Ethris GmbH
Ethris is a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines. They focus on developing innovative therapies using proprietary RNA and lipidoid nanoparticle technology platforms, with a special emphasis on delivering stabilized mRNAs directly to the respiratory system. Their mission is to improve patients' lives through advanced RNA-based treatments for respiratory diseases, immuno-modulation, protein replacement therapies, and vaccines.
Industries
Nr. of Employees
medium (51-250)
Patents
ATP-binding cassette family coding polyribonucleotides and formulations thereof
US-11479768-B2
View Details
ATP-binding cassette family coding polyribonucleotides and formulations thereof
US-11479768-B2
View DetailsProducts
Inhaled mRNA interferon-lambda candidate (lead program)
A nasal/inhaled mRNA therapeutic designed to express type III interferon locally in the respiratory mucosa to enhance antiviral innate immunity and address virus-driven exacerbations of chronic respiratory disease.
Inhaled mRNA interferon-lambda candidate (lead program)
A nasal/inhaled mRNA therapeutic designed to express type III interferon locally in the respiratory mucosa to enhance antiviral innate immunity and address virus-driven exacerbations of chronic respiratory disease.
Services
Development of inhalation and nasal formulations, including nebulized liquids and spray-dried powders, optimized for lung and nasal delivery and stability.
Build-out of CMC processes to enable transition from early clinical studies to Phase 2 readiness and GMP-compliant manufacturing.
Design and execution of Phase 1 randomized, placebo-controlled, double-blind, single-ascending-dose trials to assess safety, tolerability, and target engagement for nasal/inhaled candidates.
Development of inhalation and nasal formulations, including nebulized liquids and spray-dried powders, optimized for lung and nasal delivery and stability.
Build-out of CMC processes to enable transition from early clinical studies to Phase 2 readiness and GMP-compliant manufacturing.
Design and execution of Phase 1 randomized, placebo-controlled, double-blind, single-ascending-dose trials to assess safety, tolerability, and target engagement for nasal/inhaled candidates.
Expertise Areas
- Inhaled and nasal mRNA therapeutics
- Mucosal vaccine development
- Lipid nanoparticle formulation for pulmonary delivery
- Nebulization and nasal spray delivery optimization
Key Technologies
- Stabilized low-immunogenicity mRNA constructs
- Lipid nanoparticle encapsulation for pulmonary delivery
- Nebulization and nasal spray delivery systems
- Spray-drying and particle engineering for powder formulations
News & Updates
Ethris announced positive preliminary data from its Phase 1 clinical trial evaluating the safety, tolerability, and target engagement of ETH47, an mRNA candidate for respiratory diseases. The data shows ETH47 was generally safe, well-tolerated, and demonstrated target engagement with no severe adverse events. The full data readout is expected in Q3 2024, and the company plans to advance ETH47 for uncontrolled asthma.
Ethris announced positive preliminary data from its Phase 1 clinical trial evaluating the safety, tolerability, and target engagement of ETH47, an mRNA candidate for respiratory diseases. The data shows ETH47 was generally safe, well-tolerated, and demonstrated target engagement with no severe adverse events. The full data readout is expected in Q3 2024, and the company plans to advance ETH47 for uncontrolled asthma.